| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP of Research and Development
1 company
Francisco Silva last filed a Form 4 in October 2025, as VP of Research and Development at BRTX. Francisco Silva's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Francisco Silva a below-average insider score of 44/100, based on 11 past trades. Over a 12-month horizon, 18.2% of those trades were profitable, with an average 12-month return of -24.5%.
At the last filing, the largest reported position was 171,384 shares of BRTX. Net of sales, the BRTX filings show accumulation of 93,903 shares.
Francisco Silva has 33 Form 4 filings on record from December 2015 to October 2025, all as VP of Research and Development at BioRestorative Therapies (BRTX), 2015–2025.
The 103 reported transactions were 40 option or other derivative awards, 30 dispositions back to the company, 23 open-market purchases and 5 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 13 purchases worth about $146K and 1 sale worth about $13K.
The largest open-market purchase was 7,826 shares of BRTX at an average $6.73 on November 16, 2021, about $53K. Twelve months later BRTX was down 56%.
The only open-market sale was 3,958 shares of BRTX at an average $3.39 on August 26, 2022, about $13K. Twelve months later BRTX was down 25%.
Shares as reported in the last Form 4 for each company; the most recent is from October 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9, 2024 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 8,308 | $1.23 | $10,229.32 | +5.6% | +47.7% | +43.8% | |
| Aug 31, 2023 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 4,954 | $2.22 | $10,997.88 | +3.1% | -17.7% | -25.5% | |
| Mar 31, 2023 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 747 | $3.56 | $2,659.32 | +0.5% | +25.6% | -58.8% | |
| Nov 21, 2022 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 943 | $2.62 | $2,467.08 | +0.6% | +7.1% | -27.8% | |
| Oct 12, 2022 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 725 | $3.39 | $2,456.59 | +0.4% | -7.8% | -35.0% | |
| Oct 11, 2022 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 806 | $3.69 | $2,973.01 | +0.5% | -12.4% | -37.4% | |
| Aug 29, 2022 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 5,723 | $3.28 | $18,776.74 | +89.2% | -22.4% | -27.1% | |
| Aug 26, 2022 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Sell | 3,958 | $3.39 | $13,409.70 | -2.4% | -14.3% | -24.7% | |
| Nov 19, 2021 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 4,000 | $6.66 | $26,626.00 | +51.1% | -35.6% | -59.1% | |
| Nov 16, 2021 | BRTX Biorestorative Therapies, Inc. | VP of Research and Development | Buy | 7,826 | $6.73 | $52,631.58 | +260,867% | -37.9% | -55.6% |